Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

3518 ARTÍCULOS , VIENDO DEL 481 AL 495

Agreement between Cerebrospinal Fluid Biomarkers, Brain 18-Fluorodeoxyglucose PET, and Clinical Diagnosis in Older Adults with Cognitive Impairment

Alberto J MA, Karen G LD, Rodrigo HR, Juan de D RC, Sara G YC, Sara G AN.

Rev Invest Clin. 2024;76(5):230-237. doi: 10.24875/RIC.24000161.

Advancements and challenges in mouse models of Alzheimer's disease

Qian Z, Li Y, Ye K.

Trends Mol Med. 2024 Dec;30(12):1152-1164. doi: 10.1016/j.molmed.2024.10.010. Epub 2024 Nov 14.

Comparative neurofilament light chain trajectories in CSF and plasma in autosomal dominant Alzheimer's disease

Hofmann A, Häsler LM, Lambert M, Kaeser SA, Gräber-Sultan S, Obermüller U, Kuder-Buletta E, la Fougere C, Laske C, Vöglein J, Levin J, Fox NC, Ryan NS, Zetterberg H, Llibre-Guerra JJ, Perrin RJ, Ibanez L, Schofield PR, Brooks WS, Day GS, Farlow MR, Allegri RF, Chrem Mendez P, Ikeuchi T, Kasuga K, Lee JH, Roh JH, Mori H, Lopera F, Bateman RJ, McDade E, Gordon BA, Chhatwal JP, Jucker M, Schultz SA; Dominantly Inherited Alzheimer Network.

Nat Commun. 2024 Nov 18;15(1):9982. doi: 10.1038/s41467-024-52937-8.

Exploring the Therapeutic Potential of Noncoding RNAs in Alzheimer's Disease

Tripathi S, Sharma Y, Kumar D.

Protein Pept Lett. 2024;31(11):862-883. doi: 10.2174/0109298665335550241011080252.

Acoustic Speech Analysis in Alzheimer's Disease: A Systematic Review and Meta-Analysis

Saeedi S, Hetjens S, Grimm MOW, Barsties V Latoszek B.

J Prev Alzheimers Dis. 2024;11(6):1789-1797. doi: 10.14283/jpad.2024.132.

Blood Cathepsins on the Risk of Alzheimer's Disease and Related Pathological Biomarkers: Results from Observational Cohort and Mendelian Randomization Study

Qian XH, Ding GY, Chen SY, Liu XL, Zhang M, Tang HD.

J Prev Alzheimers Dis. 2024;11(6):1834-1842. doi: 10.14283/jpad.2024.107.

Counseling and disclosure practices in predictive Alzheimer's disease diagnostics: A scoping review

Perry J, Radenbach K, Geschke K, Rostamzadeh A.

Alzheimers Dement. 2024 Dec;20(12):8910-8936. doi: 10.1002/alz.14365. Epub 2024 Nov 19.

Public-Private Partnerships for Neuropsychiatric Drug Development: A Perspective

Potter WZ.

Adv Neurobiol. 2024;40:67-85. doi: 10.1007/978-3-031-69491-2_3.

Centiloid recommendations for clinical context-of-use from the AMYPAD consortium

Collij LE, Bollack A, La Joie R, Shekari M, Bullich S, Roé-Vellvé N, Koglin N, Jovalekic A, Garciá DV, Drzezga A, Garibotto V, Stephens AW, Battle M, Buckley C, Barkhof F, Farrar G, Gispert JD; AMYPAD consortium.

Alzheimers Dement. 2024 Dec;20(12):9037-9048. doi: 10.1002/alz.14336. Epub 2024 Nov 20.

The early diagnosis of Alzheimer's disease: Blood-based panel biomarker discovery by proteomics and metabolomics

Dong Y, Song X, Wang X, Wang S, He Z.

CNS Neurosci Ther. 2024 Nov;30(11):e70060. doi: 10.1111/cns.70060.

Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217

Kovacech B, Cullen NC, Novak P, Hanes J, Kontsekova E, Katina S, Parrak V, Fresser M, Vanbrabant J, Feldman HH, Winblad B, Stoops E, Vanmechelen E, Zilka N.

Alzheimers Res Ther. 2024 Nov 23;16(1):254. doi: 10.1186/s13195-024-01620-7.

Navigating the Alzheimer's Biomarker Landscape: A Comprehensive Analysis of Fluid-Based Diagnostics

El Abiad E, Al-Kuwari A, Al-Aani U, Al Jaidah Y, Chaari A.

Cells. 2024 Nov 18;13(22):1901. doi: 10.3390/cells13221901.

Neuroinflammatory Biomarkers in Alzheimer's Disease: From Pathophysiology to Clinical Implications

Roveta F, Bonino L, Piella EM, Rainero I, Rubino E.

Int J Mol Sci. 2024 Nov 6;25(22):11941. doi: 10.3390/ijms252211941.

Blood-based microRNAs as the potential biomarkers for Alzheimer's disease: evidence from a systematic review

Fattahi F, Asadi MR, Abed S, Kouchakali G, Kazemi M, Mansoori Derakhshan S, Shekari Khaniani M.

Metab Brain Dis. 2024 Nov 28;40(1):44. doi: 10.1007/s11011-024-01431-7.

Current status of fluid biomarkers for early Alzheimer's disease and FDA regulation implications

Jamerlan AM, An SSA, Hulme JP.

J Neurol Sci. 2024 Dec 15;467:123325. doi: 10.1016/j.jns.2024.123325. Epub 2024 Nov 22.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias